Broadly protective Shigella vaccine based on type III secretion apparatus proteins

Infection and Immunity

Volumn 80, Issue 3, 2012, Pages 1222-1231

  Martinez Becerra, Francisco J ^a   Kissmann, Julian M ^b   Diaz Mcnair, Jovita ^a   Choudhari, Shyamal P ^b   Quick, Amy M ^b   Mellado Sanchez, Gabriela ^a   Clements, John D ^c   Pasetti, Marcela F ^a   Picking, Wendy L ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL TOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SHIGELLA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE RELEASE; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; IMMUNITY; IMMUNOGENICITY; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROVOCATION TEST; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; T LYMPHOCYTE; TYPE III SECRETION SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; DYSENTERY, BACILLARY; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84857681855     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06174-11     Document Type: Article

References (56)

1. Barnoy S, et al. 2010. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 28:1642-1654.
2. Barta ML, et al. 23 December 2011, posting date. Identification of the bile salt binding site on IpaD from Shigella flexneri and the influence of ligand binding on IpaD structure. Proteins doi:10.1002/prot.23251.
3. Birket SE, et al. 2007. Preparation and characterization of translocator/chaperone complexes and their component proteins from Shigella flexneri. Biochemistry 46:8128-8137.
4. Blocker A, et al. 1999. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J. Cell Biol. 147:683-693.
5. Cam PD, Pal T, Lindberg AA. 1993. Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients. J. Clin. Microbiol. 31:454-457.
6. CDC. 2011. Vital signs: incidence and trends of infection with pathogens transmitted commonly through food-Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 1996-2010.MMWRMorb. Mortal. Wkly. Rep. 60:749-755.
7. Cohen D, et al. 1996. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun. 64:4074-4077.
8. Cohen D, Green MS, Block C, Rouach T, Ofek I. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068-1071.
9. Cohen D, Green MS, Block C, Slepon R, Ofek I. 1991. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J. Clin. Microbiol. 29:386-389.
10. Dickenson NE, et al. 2011. Conformational changes in IpaD from Shigella flexneri upon binding bile salts provide insight into the second step of type III secretion. Biochemistry 50:172-180.
11. DuPont HL, Levine MM, Hornick RB, Formal SB. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
12. Epler CR, Dickenson NE, Olive AJ, Picking WL, Picking WD. 2009. Liposomes recruit IpaC to the Shigella flexneri type III secretion apparatus needle as a final step in secretion induction. Infect. Immun. 77:2754-2761.
13. Espina M, Ausar SF, Middaugh CR, Picking WD, Picking WL. 2006. Spectroscopic and calorimetric analyses of invasion plasmid antigen D (IpaD) from Shigella flexneri reveal the presence of two structural domains. Biochemistry 45:9219-9227.
14. Espina M, et al. 2006. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect. Immun. 74:4391-4400.
15. - mutant of Shigella dysenteriae 1. Infect. Immun. 56:3099-3109.
16. Fries LF, et al. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69:4545-4553.
17. Reference deleted.
18. Johnson S, et al. 2006. Expression, limited proteolysis and preliminary crystallographic analysis of IpaD, a component of the Shigella flexneri type III secretion system. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62:865-868.
19. Katz DE, et al. 2004. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun. 72:923-930.
20. Kosek M, Yori PP, Olortegui MP. 2010. Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. Curr. Opin. Infect. Dis. 23:475-480.
21. Kotloff KL, et al. 1995. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 13:495-502.
22. Kotloff KL, et al. 2004. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J. Infect. Dis. 190:1745-1754.
23. Kotloff KL, et al. 2007. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum. Vaccin. 3:268-275.
24. Kotloff KL, et al. 1999. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77:651-666.
25. Kueltzo LA, et al. 2003. Structure-function analysis of invasion plasmid antigen C (IpaC) from Shigella flexneri. J. Biol. Chem. 278:2792-2798.
26. Le-Barillec K, et al. 2005. Roles for T and NK cells in the innate immune response to Shigella flexneri. J. Immunol. 175:1735-1740.
27. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. 2007. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5:540-553.
28. Mach H, Middaugh CR, Lewis RV. 1992. Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. Anal. Biochem. 200:74-80.
29. Mallett CP, VanDeVerg L, Collins HH, Hale TL. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:190-196.
30. Markham AP, et al. 2010. Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine. J. Pharm. Sci. 99:4497-4509.
31. McKenzie R, et al. 2006. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 24:3735-3745.
32. Menard R, Sansonetti P, Parsot C, Vasselon T. 1994. Extracellular association and cytoplasmic partitioning of the IpaB and IpaC invasins of S. flexneri. Cell 79:515-525.
33. Norton EB, Lawson LB, Freytag LC, Clements JD. 2011. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 18:546-551.
34. Oaks EV, Turbyfill KR. 2006. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 24:2290-2301.
35. Olive AJ, et al. 2007. Bile salts stimulate recruitment of IpaB to the Shigella flexneri surface, where it colocalizes with IpaD at the tip of the type III secretion needle. Infect. Immun. 75:2626-2629.
36. Passwell JH, et al. 2001. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect. Immun. 69:1351-1357.
37. Qiu S, et al. 2011. Emergence of a novel Shigella flexneri serotype 4s strain that evolved from a serotype X variant in China. J. Clin. Microbiol. 49:1148-1150.
38. Rahman KM, et al. 2011. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 29:1347-1354.
39. Ramirez K, et al. 2009. Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J. Immunol. 182:1211-1222.
40. Ramirez K, et al. 2010. Neonatal mucosal immunization with a nonliving, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol. 3:159-171.
41. Raqib R, et al. 2002. Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults. Scand. J. Immunol. 55:414-423.
42. Reed WP. 1975. Serum factors capable of opsonizing Shigella for phagocytosis by polymorphonuclear neutrophils. Immunology 28:1051-1059.
43. Riddle MS, et al. 2011. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine 29:7009-7019.
44. Samandari T, et al. 2000. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J. Immunol. 164:2221-2232.
45. Simon JK, et al. 2011. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin. Immunol. 139:185-192.
46. Srinivasa H, Baijayanti M, Raksha Y. 2009. Magnitude of drug resistant shigellosis: a report from Bangalore. Indian J. Med. Microbiol. 27:358-360.
47. Tacket CO, et al. 1992. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am. J. Trop. Med. Hyg. 47:276-283.
48. Tribble D, et al. 2010. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine 28:6076-6085.
49. Turbyfill KR, Hartman AB, Oaks EV. 2000. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect. Immun. 68:6624-6632.
50. van de Verg LL, et al. 1995. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect. Immun. 63:1947-1954.
51. Walker RI. 2005. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 23:3369-3385.
52. Way SS, Borczuk AC, Dominitz R, Goldberg MB. 1998. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect. Immun. 66:1342-1348.
53. WHO Global Alert and Response (GAR). 2004. Shigellosis in Sudan. http://www.who.int/csr/don/2004_07_14/en/.
54. WHO Initiative for Vaccine Research (IVR). 2009. Diarrhoeal diseases. http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index.html.
55. Wong MR, et al. 2010. Antimicrobial resistance trends of Shigella serotypes in New York City, 2006-2009. Microb. Drug Resist. 16:155-161.
56. Ye C, et al. 2010. Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri. J. Clin. Microbiol. 48:419-426.